AptarGroup, Inc. (NYSE:ATR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...
pharmaphorum6d
J&J builds case for antidepressant Spravato with head-to-head trial
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Medscape2d
Efficacy, Safety and Tolerability of Escitalopram in Doses up to 50 mg in Major Depressive Disorder (MDD)
Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major ...
Medscape1d
Duloxetine in the Treatment of Major Depressive Disorder: An Open-Label Study
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants ...